首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   21071篇
  免费   1247篇
  国内免费   74篇
耳鼻咽喉   155篇
儿科学   584篇
妇产科学   463篇
基础医学   3922篇
口腔科学   191篇
临床医学   2001篇
内科学   4646篇
皮肤病学   493篇
神经病学   1830篇
特种医学   770篇
外科学   3134篇
综合类   71篇
一般理论   3篇
预防医学   1156篇
眼科学   235篇
药学   1331篇
中国医学   35篇
肿瘤学   1372篇
  2023年   86篇
  2022年   106篇
  2021年   326篇
  2020年   220篇
  2019年   344篇
  2018年   554篇
  2017年   365篇
  2016年   411篇
  2015年   492篇
  2014年   623篇
  2013年   855篇
  2012年   1490篇
  2011年   1458篇
  2010年   779篇
  2009年   640篇
  2008年   1301篇
  2007年   1369篇
  2006年   1326篇
  2005年   1305篇
  2004年   1285篇
  2003年   1193篇
  2002年   1178篇
  2001年   268篇
  2000年   247篇
  1999年   249篇
  1998年   164篇
  1997年   137篇
  1996年   122篇
  1995年   110篇
  1994年   100篇
  1993年   78篇
  1992年   122篇
  1991年   112篇
  1990年   119篇
  1989年   138篇
  1988年   104篇
  1987年   116篇
  1986年   104篇
  1985年   87篇
  1984年   85篇
  1983年   60篇
  1982年   61篇
  1981年   61篇
  1979年   78篇
  1978年   61篇
  1974年   61篇
  1933年   63篇
  1932年   66篇
  1931年   63篇
  1927年   64篇
排序方式: 共有10000条查询结果,搜索用时 343 毫秒
1.
2.
3.
Graefe's Archive for Clinical and Experimental Ophthalmology -  相似文献   
4.
5.

Background

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods

Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results

Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions

No safety concerns arose, supporting the favorable benefit-risk profile of RZV.  相似文献   
6.
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly.  相似文献   
7.
8.
9.
10.
The actinobacterium strain ABH26 closely related to Saccharothrix xinjiangensis, isolated from an Algerian Saharan soil sample, exhibited highly antagonist activity against Gram-positive bacteria, yeasts and filamentous fungi. Its ability to produce antimicrobial compounds was investigated using several solid culture media. The highest antimicrobial activity was obtained on Bennett medium. The antibiotics secreted by strain ABH26 on Bennett medium were extracted by methanol and purified by reverse-phase HPLC using a C18 column. The chemical structures of the compounds were determined after spectroscopic (1H NMR, 13C NMR, 1H-1H COSY and 1H-13C HMBC spectra), and spectrometric (mass spectrum) analyses. Two new cyanogriside antibiotics named cyanogriside I (1) and cyanogriside J (2), were characterized along with three known caerulomycins, caerulomycin A (3), caerulomycin F (4) and caerulomycinonitrile (5). This is the first report of cyanogrisides and caerulomycins production by a member of the Saccharothrix genus. The minimum inhibitory concentrations (MIC) of these antibiotics were determined against pathogenic microorganisms.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号